Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Figure 4

Relationship between PD-1 and PD-L1 levels on immune cell subsets and HBsAg decline. (a) Changes of PD-1 levels on Th1 and Treg and the PD-L1 level on DCs were analyzed before and after treatment in patients with HBsAg decline ≥ 10% of C1-Group. BT: before treatment; AT: after treatment. (b) Changes of PD-1 levels on Th1 and Treg and the PD-L1 level on DCs were analyzed before and after treatment in patients with HBsAg decline ≥ 10% of T1-Group. (c) Changes of PD-1 levels on Th1 and Treg and the PD-L1 level on DCs were analyzed before and after treatment in patients with HBsAg decline ≥ 10% of C2-Group. (d) Changes of PD-1 levels on Th1 and Treg and the PD-L1 level on DCs were analyzed before and after treatment in patients with HBsAg decline ≥ 10% of T2-Group.

(a) Patients with HBsAg decline ≥ 10% in C1-Group

(b) Patients with HBsAg decline ≥ 10% in T1-Group

(c) Patients with HBsAg decline ≥ 10% in C2-Group

(d) Patients with HBsAg decline ≥ 10% in T2-Group